Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.

doi:10.1016/j.jtct.2023.12.002

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.

Transplantation and cellular therapy - 1 Feb 2024

Konuma Takaaki, Yamasaki Satoshi, Ishiyama Ken, Mizuno Shohei, Hayashi Hiromi, Uchida Naoyuki, Shimabukuro Masashi, Tanaka Masatsugu, Kuriyama Takuro, Onizuka Makoto, Ishiwata Kazuya, Sawa Masashi, Tanaka Takashi, Ohigashi Hiroyuki, Fujiwara Shin-Ichiro, Matsuoka Ken-Ichi, Ota Shuichi, Nishida Tetsuya, Kanda Yoshinobu, Fukuda Takahiro, Atsuta Yoshiko, Nakasone Hideki, Yanada Masamitsu

Abstract excerpt

Acute myeloid leukemia (AML) is the most common indication for allogeneic hematopoietic cell transplantation (HCT). The increased availability of alternative donor sources has broadened donor types for older patients without HLA-matched sibling donors (MSD). It is uncertain if an MSD should be the first option for allogeneic HCT in patients with AML over 50 years of age. The objective of this study was to compare...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fetal Blood

Share to Graft vs Host Disease

Share to Hematopoietic Stem Cell Transplantation

Share to Leukemia, Myeloid, Acute

Share to Siblings

Share to Transplantation, Homologous

Share to Unrelated Donors

Source

Open in PubMed

Identifiers

PMID: 38081415
DOI: 10.1016/j.jtct.2023.12.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Allogeneic Transplant Outcomes Between Matched Sibling Donors and Alternative Donors in Patients Over 50 Years of Age with Acute Myeloid Leukemia: 8/8 Allele-Matched Unrelated Donors and Unrelated Cord Blood Provide Better Leukemia-Free Survival Compared with Matched Sibling Donors During Nonremission Status.PMID 38081415Read ↗

Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia.Semantic proximity Read ↗

Comparison of Outcomes of 8/8 and 7/8 Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Cord Blood Transplantation in Adults with Acute Leukemia.Semantic proximity Read ↗

A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemiaSemantic proximity Read ↗

Potential Impact of HLA DQB1*05 on Identical Sibling Hemato-Poietic Stem Cell Transplantation OutcomeSemantic proximity Read ↗

Significant Improvement in Survival after Unrelated Donor Hematopoietic Cell Transplantation in the Recent EraSemantic proximity Read ↗

HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable or intermediate risk acute myeloid leukemiaSemantic proximity Read ↗

Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching analysis over the last decadeSemantic proximity Read ↗

One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donorsSemantic proximity Read ↗

Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters MostSemantic proximity Read ↗

Second allogeneic haematopoietic cell transplantation using HLA‐matched unrelated versus T‐cell replete haploidentical donor and survival in relapsed acute myeloid leukaemiaSemantic proximity Read ↗

Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.